Search results for "antiviral agent"

showing 10 items of 505 documents

Optimum combination therapy regimens for HIV/HCV infection

2016

HIV-HCV co-infection mostly affects intravenous drug users, in whom prevalence has tended to decrease in recent years, while it has increased in men who have sex with men, with occurrence of acute hepatitis C. Hepatitis C has a poorer prognosis in patients co-infected with HIV, as clinical progression is faster and degree of hepatic fibrosis is greater. However, optimized ARV treatment is clearly associated with slower progression to hepatic complications. Interactions between HCV and HIV drugs are numerous, which underlines the importance of pharmacological advice for HIV-treated patients before they start HCV treatment. In HIV-HCV co-infection, treatment of hepatitis C has to be offered a…

Microbiology (medical)medicine.medical_specialtyCombination therapyHIV InfectionsHepatic ComplicationAntiviral AgentsMicrobiologyMen who have sex with men03 medical and health sciences0302 clinical medicineVirologyInternal medicineGenotypemedicineHumansDrug Interactions030212 general & internal medicineStage (cooking)Coinfectionbusiness.industryvirus diseasesHepatitis Cmedicine.diseaseHepatitis CInfectious DiseasesImmunologyCoinfectionDrug Therapy Combination030211 gastroenterology & hepatologyHepatic fibrosisbusinessExpert Review of Anti-infective Therapy
researchProduct

Current and future challenges in HCV: insights from an Italian experts panel

2017

Background: The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages. Methods: A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens. Results and conclusions: Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated …

Microbiology (medical)medicine.medical_specialtySettore MED/17 - Malattie InfettiveDisease stagesComorbidityAntiviral AgentsComorbiditiesVirological response03 medical and health sciences0302 clinical medicineComorbidities; DAAs; HCV; Treatment; Microbiology (medical); Infectious DiseasesmedicineHumans030212 general & internal medicineIntensive care medicineDAAHigh rateComorbidities; DAAs; HCV; Treatmentbusiness.industryDAAsGeneral MedicineHepatitis Cmedicine.diseaseHepatitis CVirologyTreatmentInfectious DiseasesItalyTolerabilityComorbidities; DAAs; HCV; Treatment; Comorbidity; Hepatitis C; Humans; Italy; Antiviral AgentsHealthcare settingsHCV030211 gastroenterology & hepatologyComorbiditiebusinessDirect acting
researchProduct

Social evolution of innate immunity evasion in a virus

2019

Antiviral immunity has been studied extensively from the perspective of virus−cell interactions, yet the role of virus−virus interactions remains poorly addressed. Here, we demonstrate that viral escape from interferon (IFN)-based innate immunity is a social process in which IFN-stimulating viruses determine the fitness of neighbouring viruses. We propose a general and simple social evolution framework to analyse how natural selection acts on IFN shutdown and validate it in cell cultures and mice infected with vesicular stomatitis virus. Furthermore, we find that IFN shutdown is costly because it reduces short-term viral progeny production, thus fulfilling the definition of an altruistic tr…

Microbiology (medical)virusesImmunologyBiologyApplied Microbiology and BiotechnologyMicrobiologyAntiviral AgentsModels BiologicalArticleVirusVesicular stomatitis Indiana virus03 medical and health sciencesMiceViral ProteinsInterferonImmunityGeneticsmedicineAnimals030304 developmental biologyImmune Evasion0303 health sciencesMice Inbred BALB CInnate immune systemNatural selection030306 microbiologyBrainCell BiologyDNA-Directed RNA Polymerasesbiology.organism_classificationAltruismVirologyBiological EvolutionImmunity Innate3. Good healthDisease Models AnimalVesicular stomatitis virusViral evolutionHost-Pathogen InteractionsFemaleInterferonsSocial evolutionmedicine.drugNature Microbiology
researchProduct

In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection

2020

COVID-19 is a pandemic health emergency faced by the entire world. The clinical treatment of the severe acute respiratory syndrome (SARS) CoV-2 is currently based on the experimental administration of HIV antiviral drugs, such as lopinavir, ritonavir, and remdesivir (a nucleotide analogue used for Ebola infection). This work proposes a repurposing process using a database containing approximately 8000 known drugs in synergy structure- and ligand-based studies by means of the molecular docking and descriptor-based protocol. The proposed in silico findings identified new potential SARS CoV-2 main protease (MPRO) inhibitors that fit in the catalytic binding site of SARS CoV-2 MPRO. Several sel…

Models Molecular0301 basic medicineAgingmedicine.medical_treatmentcoronaviruslcsh:QR1-502Viral Nonstructural Proteinsmedicine.disease_causelcsh:Microbiology0302 clinical medicineSettore BIO/10 - BiochimicaCoronavirus 3C ProteasesCoronavirusvirus diseasesLopinavirHypothesisMolecular Docking SimulationCysteine EndopeptidasesDrug repositioningInfectious Diseases030220 oncology & carcinogenesisCoronavirus InfectionsOxidation-Reductionmedicine.drugDNA damageIn silicoPneumonia ViralBiologyAntiviral AgentsHIV-proteaseBetacoronavirus03 medical and health sciencesSARS-CoV-2 main proteaseVirologymedicineHumansComputer SimulationProtease InhibitorsPandemicsBinding SitesProteaseSARS-CoV-2Drug RepositioningCOVID-19HIV Protease InhibitorsDRUDIT web servicemolecular dockingNADbiology.organism_classificationVirologySettore CHIM/08 - Chimica FarmaceuticaCOVID-19 Drug Treatmentcoronaviru030104 developmental biologyNADHRitonavirBetacoronavirusDNA Damage
researchProduct

The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations

2020

Graphical abstract The inorganic physiological polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations. This discovery proposes polyphosphate as a new member of the host's antiviral innate immune defense.

Models Molecular0301 basic medicineAntiviral AgentsBiochemistryArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePolyphosphatesPolyphosphateHuman Umbilical Vein Endothelial Cellsotorhinolaryngologic diseasesHumansPlateletReceptorneoplasmsPharmacologychemistry.chemical_classificationBinding assayInnate immune systemSARS-CoV-2 spike S-proteinLigand binding assayPolyphosphateCOVID-19pathological conditions signs and symptomsdigestive system diseasesCOVID-19 Drug TreatmentAmino acidsurgical procedures operative030104 developmental biologyEnzymechemistryBiochemistry030220 oncology & carcinogenesisSpike Glycoprotein CoronavirusNanoparticlesAlkaline phosphataseAngiotensin-Converting Enzyme 2Protein BindingReceptors CoronavirusBiochemical Pharmacology
researchProduct

Flavonoids as noncompetitive inhibitors of Dengue virus NS2B-NS3 protease: Inhibition kinetics and docking studies

2014

NS2B-NS3 is a serine protease of the Dengue virus considered a key target in the search for new antiviral drugs. In this study flavonoids were found to be inhibitors of NS2B-NS3 proteases of the Dengue virus serotypes 2 and 3 with IC50 values ranging from 15 to 44 μM. Agathisflavone (1) and myricetin (4) turned out to be noncompetitive inhibitors of dengue virus serotype 2 NS2B-NS3 protease with Ki values of 11 and 4.7 μM, respectively. Docking studies propose a binding mode of the flavonoids in a specific allosteric binding site of the enzyme. Analysis of biomolecular interactions of quercetin (5) with NT647-NHS-labeled Dengue virus serotype 3 NS2B-NS3 protease by microscale thermophoresis…

Models MolecularProteasesSerine Proteinase Inhibitorsvirusesmedicine.medical_treatmentClinical BiochemistryPharmaceutical ScienceDengue virusmedicine.disease_causeAntiviral AgentsBiochemistryStructure-Activity Relationshipchemistry.chemical_compoundDrug DiscoverymedicineMolecular BiologyFlavonoidsSerine proteaseNS3ProteasebiologyMicroscale thermophoresisSerine EndopeptidasesOrganic ChemistryDengue VirusVirologyMolecular Docking SimulationKineticschemistryBiochemistryDocking (molecular)biology.proteinMolecular MedicineMyricetinBioorganic & Medicinal Chemistry
researchProduct

The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy

1999

The hepatitis C virus (HCV) is a major causative agent of transfusion-acquired and sporadic non-A, non-B hepatitis worldwide. Infections most often persist and lead, in approximately 50% of all patients, to chronic liver disease. As is characteristic for a member of the family Flaviviridae, HCV has a plus-strand RNA genome encoding a polyprotein, which is cleaved co- and post-translationally into at least 10 different products. These cleavages are mediated, among others, by a virally encoded chymotrypsin-like serine proteinase located in the N-terminal domain of non-structural protein 3 (NS3). Activity of this enzyme requires NS4A, a 54-residue polyprotein cleavage product, to form a stable…

Models MolecularProtein ConformationvirusesHepatitis C virusMolecular Sequence DataHepacivirusViral Nonstructural ProteinsBiologymedicine.disease_causeAntiviral AgentsSerineProtein structureVirologymedicineProtease InhibitorsAmino Acid SequenceHepatitischemistry.chemical_classificationNS3HepatologySerine EndopeptidasesRNAmedicine.diseaseVirologyNS2-3 proteaseInfectious DiseasesEnzymechemistryRNA HelicasesJournal of Viral Hepatitis
researchProduct

Synthesis of C-17-functionalized spongiane diterpenes: diastereoselective synthesis of (-)-spongian-16-oxo-17-al, (-)-acetyldendrillol-1, and (-)-apl…

2003

The diastereoselective synthesis of spongiane diterpenes (-)-spongian-16-oxo-17-al 2, (-)-acetyldendrillol-1 15, and (-)-aplyroseol-14 16 has been completed efficiently via the common intermediate 14. Compound 14 was prepared in five synthetic steps from (+)-podocarp-8(14)-en-13-one 13, easily available from commercial (-)-abietic acid. The key steps in the syntheses were a regioselective reduction of a 1,4-dialdehyde unit, a one-pot acetalization-acetylation, and a translactonization. The synthesis of 15 and 16 has led us to a revision of the configuration at C-17 for natural (-)-acetyldendrillol-1 and a structural reassignment for aplyroseol-14. Thus, aplyroseol-14 16 presents an unpreced…

Models MolecularStereochemistryHerpesvirus 2 HumanMolecular ConformationAntineoplastic AgentsAldehydeChemical synthesisAntiviral AgentsCatalysischemistry.chemical_compoundAb initio quantum chemistry methodsTumor Cells CulturedAnimalsHumansNuclear Magnetic Resonance Biomolecularchemistry.chemical_classificationNatural productMolecular StructureOrganic ChemistryRegioselectivityStereoisomerismPhenanthrenesPoriferachemistryAbietanesIndicators and ReagentsDiterpeneDiterpenesEnoneLactoneHeLa CellsThe Journal of organic chemistry
researchProduct

Virtual Combinatorial Syntheses and Computational Screening of New Potential Anti-Herpes Compounds

1999

The activity of new anti-HSV-1 chemical structures, designed by virtual combinatorial chemical synthesis and selected by a computational screening, is determined by an in vitro assay. A virtual library of phenol esters and anilides was formed from two databases of building blocks: one with carbonyl fragments and the other containing both substituted phenoxy and phenylamino fragments. The library of virtually assembled compounds was computationally screened, and those compounds which were selected by our mathematical model as active ones were finally synthesized and tested. Our antiviral activity model is a "tandem" of four linear functions of topological graph-theoretical descriptors. A giv…

Models Molecularmedicine.drug_classStereochemistryChemical structureCarboxamideHerpesvirus 1 HumanViral Plaque AssayAntiviral AgentsChemical synthesisInhibitory Concentration 50Structure-Activity RelationshipPhenolsChlorocebus aethiopsDrug DiscoverymedicineIc50 valuesAnimalsStructure–activity relationshipAnilidesVero Cellschemistry.chemical_classificationBicyclic moleculeTandemChemistryEstersDicarboxylic acidMolecular MedicineJournal of Medicinal Chemistry
researchProduct

Antiviral efficacy of cerium oxide nanoparticles.

2022

The authors gratefully acknowledge the financial support by the Estonian Research Council Grants (COVSG2, PRG629, PRG1496), Estonian Centre of Excellence in Research project “Advanced materials and high-technology devices for sustainable energetics, sensorics and nanoelectronics” TK141 (2014-2020.4.01.15-0011) and University of Tartu Development Fund (PLTFYARENG53). The research was partly conducted using the NAMUR+ core facility funded by projects “Center of nanomaterials technologies and research” (2014-2020.4.01.16-0123) and TT13.

MultidisciplinarySilverSARS-CoV-2HumansMetal NanoparticlesCOVID-19Nanoparticles:NATURAL SCIENCES::Physics [Research Subject Categories]CeriumSilicon DioxideAntiviral AgentsScientific reports
researchProduct